Independent Analysis of Clinical Trial Data: GS1 Continuous Glucose Monitoring System (CGMS) in Pediatric Diabetes Management

Authors

  • Barkin Berk Istanbul Okan University, Faculty of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Tuzla, Istanbul-Turkey

Abstract

Background: Diabetes mellitus poses significant challenges in pediatric populations, necessitating advanced glycemic monitoring technologies. This study presents an independent analysis of the GS1 Continuous Glucose Monitoring System (CGMS), originally developed by Shenzhen SiSensing Co., Ltd., and provided by its Turkish partner, BMED Pharmaceuticals. The analysis evaluates the efficacy, safety, and usability of the GS1 CGMS in pediatric patients aged 3 to under 18 years with diabetes mellitus.

Methods: This multicenter, prospective trial included 81 pediatric participants across three clinical centers in China: Beijing Children’s Hospital, Capital Medical University (Center 01); Shenzhen Children’s Hospital (Center 02); and Fujian Medical University Union Hospital (Center 03). Participants underwent 14 days of CGMS monitoring, with venous blood glucose measurements as reference. Key metrics included concordance rates within the 20/20% error range, Clarke and Consensus Error Grid analyses, and Mean Absolute Relative Difference (MARD%). Safety and usability were assessed through adverse event monitoring and participant feedback.

Results: A total of 79 participants completed the trial, achieving a 97.5% completion rate. Concordance rates were 93.9% across all glycemic ranges, surpassing predefined thresholds. Sensitivity and specificity for hypoglycemia detection were 97.6% and 87.3%, respectively, while hyperglycemia detection achieved 89.8% sensitivity and 97.0% specificity. The MARD% was 8.7%, consistently below the target of 18%. Usability scores averaged 95.3 ± 7.59, reflecting high satisfaction. Device-related adverse events, such as mild skin irritation, were self-limiting, and no serious adverse events were reported.

Conclusion: This independent analysis demonstrated that the GS1 CGMS offers high accuracy, safety, and usability in pediatric glycemic monitoring. These findings support its broader application in routine pediatric diabetes care. Future studies should explore long-term efficacy and comparative evaluations with other CGMS technologies.

Keywords Independent analysis, Continuous Glucose Monitoring (CGM), GS1 CGMS, Pediatric diabetes patients

Keywords:

Independent analysis, Continuous Glucose Monitoring (CGM), GS1 CGMS, Pediatric diabetes patients

DOI

https://doi.org/10.22270/jddt.v14i11.6934

Author Biography

Barkin Berk , Istanbul Okan University, Faculty of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Tuzla, Istanbul-Turkey

Istanbul Okan University, Faculty of Pharmacy, Department of Pharmaceutical and Medicinal Chemistry, Tuzla, Istanbul-Turkey

References

1. International Diabetes Federation. IDF Diabetes Atlas, 10th edition. 2021. https://diabetesatlas.org/

2. World Health Organization. Diabetes. https://www.who.int/news-room/fact-sheets/detail/diabetes

3. Deshpande AD, Harris-Hayes M, Schootman M. Epidemiology of diabetes and diabetes-related complications. Phys Ther. 2008 Nov;88(11):1254-64. https://pubmed.ncbi.nlm.nih.gov/18801858/ https://doi.org/10.2522/ptj.20080020 PMid:18801858 PMCid:PMC3870323

4. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53. https://pubmed.ncbi.nlm.nih.gov/15111519/ https://doi.org/10.2337/diacare.27.5.1047 PMid:15111519

5. Ludvigsson J. Continuous subcutaneous glucose monitoring improved metabolic control in pediatric patients with type 1 diabetes: a controlled crossover study. Pediatrics. 2003 May;111(5 Pt 1):933-8. https://pubmed.ncbi.nlm.nih.gov/12728076/ https://doi.org/10.1542/peds.111.5.933 PMid:12728068

6. Kaufman FR, Gibson LC, Halvorson M, Carpenter S, Fisher LK, Pitukcheewanont P. A pilot study of the continuous glucose monitoring system: clinical decisions and glycemic control after its use in pediatric type 1 diabetic subjects. Diabetes Care. 2001 Dec;24(12):2030-4. https://pubmed.ncbi.nlm.nih.gov/11723080/ https://doi.org/10.2337/diacare.24.12.2030 PMid:11723078

7. Gross TM, Bode BW, Einhorn D, Kayne D, Reed JH, White NH, Mastrototaro JJ. Performance evaluation of the MiniMed continuous glucose monitoring system during patient home use. Diabetes Technol Ther. 2000;2(1):49-56. https://pubmed.ncbi.nlm.nih.gov/11467319/ https://doi.org/10.1089/152091500316737 PMid:11467320

8. Juvenile Diabetes Research Foundation Continuous Glucose Monitoring Study Group. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct 2;359(14):1464-76. https://pubmed.ncbi.nlm.nih.gov/18779236/ https://doi.org/10.1056/NEJMoa0805017 PMid:18779236

9. Tamborlane WV, Beck RW, Bode BW, et al. Continuous glucose monitoring and intensive treatment of type 1 diabetes. N Engl J Med. 2008 Oct;359:1464-76. https://pubmed.ncbi.nlm.nih.gov/18779236/ https://doi.org/10.1056/NEJMoa0805017 PMid:18779236

10. Bode BW, Steed RD, Davidson PC. Reduction in severe hypoglycemia with long-term continuous subcutaneous insulin infusion in type 1 diabetes. Diabetes Care. 1996 Mar;19(3):324-7. https://pubmed.ncbi.nlm.nih.gov/8742560/ https://doi.org/10.2337/diacare.19.4.324 PMid:8729154

Published

24-12-2024
Statistics
Abstract Display: 78
PDF Downloads: 35
PDF Downloads: 0

How to Cite

1.
Berk B. Independent Analysis of Clinical Trial Data: GS1 Continuous Glucose Monitoring System (CGMS) in Pediatric Diabetes Management. J. Drug Delivery Ther. [Internet]. 2024 Dec. 24 [cited 2025 Feb. 13];14(11):128-35. Available from: https://jddtonline.info/index.php/jddt/article/view/6934

How to Cite

1.
Berk B. Independent Analysis of Clinical Trial Data: GS1 Continuous Glucose Monitoring System (CGMS) in Pediatric Diabetes Management. J. Drug Delivery Ther. [Internet]. 2024 Dec. 24 [cited 2025 Feb. 13];14(11):128-35. Available from: https://jddtonline.info/index.php/jddt/article/view/6934